Genetic Profiling in the Australian Ovarian Cancer Study

Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis

K Gersekowski, R Na, K Alsop, R Delahunty, EL Goode, JM Cunningham, SJ Winham, PDP Pharoah, H Song, PM Webb

2024-04-01

Background: Women with an inherited pathogenic variant in BRCA1 or BRCA2 have a greatly increased risk of developing ovarian cance..

Germline BRCA variants, lifestyle and ovarian cancer survival

K Gersekowski, R Delahunty, K Alsop, EL Goode, JM Cunningham, SJ Winham, P Pharoah, H Song, S Jordan, S Fereday, A DeFazio, M Friedlander, A Obermair, PM Webb

2022-06-01

Objective: Women with ovarian cancer who have a pathogenic germline variant in BRCA1 or BRCA2 (BRCA) have been shown to have bette..

19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes

D Aziz, D Etemadmoghadam, CE Caldon, G Au-Yeung, N Deng, R Hutchinson, D Bowtell, P Waring

2018-11-01

Objectives: Readily apparent cyclin E1 expression occurs in 50% of HGSOC, but only half are linked to 19q12 locus amplification. T..

Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer

DW Garsed, K Alsop, S Fereday, C Emmanuel, CJ Kennedy, D Etemadmoghadam, B Gao, V Gebski, V Gares, EL Christie, MCA Wouters, K Milne, J George, AM Patch, J Li, GM Arnau, T Semple, SR Gadipally, YE Chiew, J Hendley

2018-02-01

Purpose: Women with epithelial ovarian cancer generally have a poor prognosis; however, a subset of patients has an unexpected dra..

Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer

SJ Ramus, H Song, E Dicks, JP Tyrer, AN Rosenthal, MP Intermaggio, L Fraser, A Gentry-Maharaj, J Hayward, S Philpott, C Anderson, CK Edlund, D Conti, P Harrington, D Barrowdale, DD Bowtell, K Alsop, G Mitchell, MS Cicek, JM Cunningham

2015-11-01

Background: Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, responsible for 13 000 deaths per year in..

Connecting patients, researchers and clinical genetics services: The experiences of participants in the Australian ovarian cancer study (AOCS)

A Crook, L Plunkett, LE Forrest, N Hallowell, S Wake, K Alsop, M Gleeson, D Bowtell, G Mitchell, MA Young

2015-02-20

Population-based genetic research may produce information that has clinical implications for participants and their family. Resear..

Synthetic lethality between CCNE1 amplification and loss of BRCA1

D Etemadmoghadam, BA Weir, G Au-Yeung, K Alsop, G Mitchell, J George, S Davis, AD D'Andrea, K Simpson, WC Hahn, DDL Bowtell

2013-11-26

High-grade serous ovarian cancers (HGSCs) are characterized by a high frequency of TP53 mutations, BRCA1/2 inactivation, homologou..

No evidence for PALB2 methylation in high-grade serous ovarian cancer

T Mikeska, K Alsop, G Mitchell, DD Bowtell, A Dobrovic

2013-05-06

Background: High-grade serous ovarian cancers are a distinct histological subtype of ovarian cancer often characterised by a dysfu..

High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival

LOB Baumbusch, AH Helland, YW Wang, KL Liestol, MES Schaner, RH Holm, D Etemadmoghadam, KA Alsop, PB Brown, G Mitchell, SF Fereday, AD DeFazio, DD Bowtell, GBK Kristensen, OCL Lingjaerde, AB Borresen-Dale

2013-01-01

Genomic instability and copy number alterations in cancer are generally associated with poor prognosis; however, recent studies ha..

The responses of research participants and their next of kin to receiving feedback of genetic test results following participation in the Australian Ovarian Cancer Study

N Hallowell, K Alsop, M Gleeson, A Crook, L Plunkett, D Bowtell, G Mitchell, MA Young

2013-01-01

Purpose: The generation of clinically significant genetic data during research studies raises a number of ethical issues about the..